secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001628280-26-017885
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen raises $35.75M, reports positive EBD preclinical data with 14-40x brain penetration
--------------------------------------------------------------------------------

- Gross proceeds of $35.75M from private placement of 10,833,331 shares at $3.30/share; led by RA Capital.
- Preclinical data for EBD program: 14-40x brain levels in NHPs vs. native antibodies; low anemia risk.
- Subcutaneous dosing feasible; IND submission for lead candidate targeted for mid-2027.
- Proceeds primarily to support EBD program preclinical work and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/0001628280-26-017885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/abos-20260313.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-017885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer